Industries > Pharma > Global Anti-Epilepsy Drugs Market Forecast 2017-2027

Global Anti-Epilepsy Drugs Market Forecast 2017-2027

First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin

PUBLISHED: 12 May 2017
PAGES: 145
PRODUCT CODE: PHA0193
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0193 Categories: ,

The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 145-page report you will receive 100 charts – all unavailable elsewhere.

The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Anti-Epilepsy Drugs Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets:
– First-generation Drugs
– Second-generation Drugs
– Third-generation Drugs
– Others

Global Anti-Epilepsy Drugs Market Forecast 2017-2027

• This report also discusses the leading anti-epilepsy drugs:
– Vimpat
– Keppra
– Briviact
– Lamictal
– Potiga/Trobalt
– Lyrica
– Neurontin

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
– US
– Japan
– EU5
– BRIC
– RoW

• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK

• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market

• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy

• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market

• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.

Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Epilepsy Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Anti-Epilepsy Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

READ

Categories